TRANSGENE BIOTEK LTD. Share Price
TRANSGENE BIOTEK LTD. Share Price Today
As of 5 Jul 2026, TRANSGENE BIOTEK LTD. share price is ₹2.96. The stock opened at ₹3.06, compared to its previous close of ₹3.04. During today's trading session, TRANSGENE BIOTEK LTD. share price moved in the range of ₹2.96 to ₹3.10, with an average price of ₹3.03 for the day. Looking at its last 52-week, the stock has touched a low of ₹1.83 and a high of ₹5.26.
TRANSGENE BIOTEK LTD. Returns Calculator
TRANSGENE BIOTEK LTD. Shareholder Returns
TRANSGENE BIOTEK LTD. Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Apollo Hospitals | 1,25,057.00 | 62.45 | 13.20 | 20.48% | 0.32 | 17.27% | 692.92 | 0.23% | 0.70 | 103.81 |
| Max Healthcare | 1,09,728.00 | 76.08 | 10.21 | 13.42% | 0.09 | 12.97% | 91.86 | 0.18% | 0.28 | 7.37 |
| Fortis Healthcare | 73,604.60 | 69.15 | 7.44 | 10.53% | 0.23 | 12.56% | 122.24 | 0.10% | 0.16 | 3.05 |
| Aster DM Healthcare | 40,962.60 | 95.95 | 9.69 | 8.48% | 0.31 | 10.10% | 83.23 | 0.38% | 0.46 | 5.20 |
| Narayana Hrudayalaya | 40,570.70 | 50.34 | 8.94 | 17.76% | 0.76 | 11.42% | 127.10 | 0.23% | 0.85 | 24.77 |
| Global Health | 36,176.70 | 65.28 | 9.13 | 14.05% | 0.06 | 15.26% | 149.24 | 0.04% | 0.77 | 18.46 |
| KRISHNA INST OF MED SCI L | 35,097.80 | 145.08 | 9.37 | 10.74% | 0.63 | 7.99% | 93.54 | 0.00% | 0.46 | 6.52 |
| Dr. Lal Path Labs | 27,697.10 | 54.33 | 11.04 | 20.13% | 0.07 | 25.56% | 8.90 | 1.56% | 1.01 | 30.45 |
| Syngene International | 17,755.40 | 56.03 | 3.67 | 7.76% | 0.04 | 9.67% | 116.55 | 0.28% | 0.67 | 7.58 |
| Poly Medicure | 17,614.20 | 54.92 | 5.67 | 10.37% | 0.08 | 12.71% | 301.18 | 0.20% | 0.53 | 33.15 |
TRANSGENE BIOTEK LTD. Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹0.26 | ₹0.23 | ₹0.06 | ₹0.09 |
| Other Income | ₹0.78 | ₹0.18 | ₹0.18 | ₹0.21 |
| Total Revenue | ₹1.04 | ₹0.42 | ₹0.23 | ₹0.30 |
| Total Expenses | ₹1.72 | ₹1.07 | ₹6.24 | ₹10.70 |
| Profit Before Tax | -₹0.68 | -₹0.66 | -₹6.01 | -₹10.40 |
| Tax | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 |
| Profit After Tax | -₹0.68 | -₹0.66 | -₹6.01 | -₹10.40 |
| EPS - Basic | -₹0.09 | -₹0.09 | -₹0.79 | -₹1.37 |
| EPS - Diluted | -₹0.09 | -₹0.09 | -₹0.79 | -₹1.37 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | -₹0.68 | -₹0.66 | -₹6.01 | -₹10.40 |
| Income before WC changes | -₹0.52 | -₹0.61 | -₹1.05 | -₹0.43 |
| Change in Assets | ₹0.12 | -₹0.06 | -₹0.13 | -₹0.05 |
| Change in Liabilities | ₹1.60 | ₹0.67 | ₹1.18 | ₹0.58 |
| Change in WC | ₹1.72 | ₹0.61 | ₹1.05 | ₹0.52 |
| Cash flow from Operations | ₹1.20 | ₹0.00 | ₹0.00 | ₹0.10 |
| Cash flow from Investing | -₹1.70 | ₹0.00 | -₹0.01 | -₹0.10 |
| Cash flow from Financing | ₹0.78 | ₹0.00 | ₹0.00 | ₹0.00 |
| Total Cash Flow | ₹0.28 | ₹0.00 | -₹0.01 | ₹0.00 |
| Cash (Start of the year) | ₹0.01 | ₹0.00 | ₹0.02 | ₹0.01 |
| Cash (End of the year) | ₹0.28 | ₹0.01 | ₹0.00 | ₹0.02 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹142.83 | ₹141.22 | ₹141.31 | ₹146.40 |
| Current Assets | ₹1.26 | ₹1.11 | ₹1.04 | ₹0.70 |
| Total Assets | ₹144.09 | ₹142.33 | ₹142.36 | ₹147.10 |
| Current Liabilities | ₹12.74 | ₹11.14 | ₹10.47 | ₹9.21 |
| Net Current Asset | -₹11.47 | -₹10.03 | -₹9.42 | -₹8.51 |
| Non-Current Liabilities | ₹121.32 | ₹120.48 | ₹120.52 | ₹120.52 |
| Equity Capital | ₹10.03 | ₹10.71 | ₹11.37 | ₹17.38 |
| Total Equity & Liabilities | ₹144.09 | ₹142.33 | ₹142.36 | ₹147.10 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹0.26 | ₹0.23 | ₹0.06 | ₹0.09 |
| Other Income | ₹0.78 | ₹0.18 | ₹0.18 | ₹0.21 |
| Total Revenue | ₹1.04 | ₹0.42 | ₹0.23 | ₹0.30 |
| Total Expenses | ₹1.72 | ₹1.07 | ₹6.24 | ₹10.70 |
| Profit Before Tax | -₹0.68 | -₹0.66 | -₹6.01 | -₹10.40 |
| Tax | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 |
| Profit After Tax | -₹0.68 | -₹0.66 | -₹6.01 | -₹10.40 |
| EPS - Basic | -₹0.09 | -₹0.09 | -₹0.79 | -₹1.37 |
| EPS - Diluted | -₹0.09 | -₹0.09 | -₹0.79 | -₹1.37 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | -₹0.68 | -₹0.66 | -₹6.01 | -₹10.40 |
| Income before WC changes | -₹0.52 | -₹0.61 | -₹1.05 | -₹0.43 |
| Change in Assets | ₹0.12 | -₹0.06 | -₹0.13 | -₹0.05 |
| Change in Liabilities | ₹1.59 | ₹0.67 | ₹1.18 | ₹0.58 |
| Change in WC | ₹1.71 | ₹0.61 | ₹1.05 | ₹0.52 |
| Cash flow from Operations | ₹1.20 | ₹0.00 | ₹0.00 | ₹0.10 |
| Cash flow from Investing | -₹1.70 | ₹0.00 | -₹0.01 | -₹0.10 |
| Cash flow from Financing | ₹0.78 | ₹0.00 | ₹0.00 | ₹0.00 |
| Total Cash Flow | ₹0.28 | ₹0.00 | -₹0.01 | ₹0.00 |
| Cash (Start of the year) | ₹0.01 | ₹0.00 | ₹0.02 | ₹0.01 |
| Cash (End of the year) | ₹0.28 | ₹0.01 | ₹0.00 | ₹0.02 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹32.95 | ₹31.34 | ₹31.44 | ₹36.53 |
| Current Assets | ₹1.26 | ₹1.10 | ₹1.04 | ₹0.69 |
| Total Assets | ₹34.20 | ₹32.44 | ₹32.48 | ₹37.22 |
| Current Liabilities | ₹12.63 | ₹11.04 | ₹10.36 | ₹9.10 |
| Net Current Asset | -₹11.37 | -₹9.93 | -₹9.33 | -₹8.41 |
| Non-Current Liabilities | ₹29.12 | ₹28.28 | ₹28.32 | ₹28.32 |
| Equity Capital | -₹7.55 | -₹6.87 | -₹6.21 | -₹0.20 |
| Total Equity & Liabilities | ₹34.20 | ₹32.44 | ₹32.48 | ₹37.22 |
About TRANSGENE BIOTEK LTD.
Transgene Biotek Limited is an India-based biotechnology company. It is engaged in the research and development of vaccines, oncology, and new drug delivery technologies. Its portfolio of products includes oncology, autoimmunity, drug delivery and biogenetics. The Company offers TrabiAAV, which is a platform for the delivery of micro-ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy and CRISPR/cas 9 technologies. Its monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL drug is focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-1203 drug is used to strengthen cell-mediated immunity and complete the elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus drug suppresses the immune system and is mainly used to prevent rejection of transplanted organs.
TRANSGENE BIOTEK LTD. Financial Highlights
- Revenue: TRANSGENE BIOTEK LTD. reported revenue of ₹0.36 crore in FY26 vs ₹1.04 crore in FY25. It showed a decrease of 65.38% on a yearly basis.
- Operating Profit: TRANSGENE BIOTEK LTD. reported an operating loss of ₹1.65 crore in FY26 vs ₹0.68 crore in FY25. It showed a decrease of 142.65% on a year-on-year basis.
- Net Profit: TRANSGENE BIOTEK LTD. reported a net loss of ₹1.65 crore in FY26 vs ₹0.68 crore in FY25. It showed a decrease of 142.65% on a yearly basis.
TRANSGENE BIOTEK LTD. Quarterly Result Highlights
- TRANSGENE BIOTEK LTD. reported revenue of ₹0.20 crore in Mar 2026, compared with ₹0.05 crore in Dec 2025, representing an increase of 300.00% on a quarter-on-quarter (QoQ) basis.
- TRANSGENE BIOTEK LTD. reported an operating loss of ₹0.46 crore in Mar 2026, compared with ₹0.37 crore in Dec 2025, representing a decrease of 24.32% on a quarter-on-quarter (QoQ) basis.
- TRANSGENE BIOTEK LTD. reported a loss of ₹0.46 crore in Mar 2026, compared with ₹0.37 crore in Dec 2025, reflecting a decrease of 24.32% on a QoQ basis.
- The earnings per share (EPS) of TRANSGENE BIOTEK LTD. stood at ₹0.09 during Mar 2026.
Similar Stocks
FAQs on TRANSGENE BIOTEK LTD. Share Price
What is TRANSGENE BIOTEK LTD. share price today?
TRANSGENE BIOTEK LTD. share price is ₹2.96 as on 03 Jul, 2026, 15:29 IST.
How has the TRANSGENE BIOTEK LTD. share price performed in the past?
In the last 1 year, TRANSGENE BIOTEK LTD. delivered a return of -37.42%. The TRANSGENE BIOTEK LTD. share price hit a high of ₹5.26 and low of ₹1.83.
How much is the Mutual Fund shareholding in TRANSGENE BIOTEK LTD. shares?
The Mutual Fund Shareholding in TRANSGENE BIOTEK LTD. was 0.00% at the end of Mar 2026.
What is the the 52-week high and low of TRANSGENE BIOTEK LTD. shares ?
The 52-week high and low of TRANSGENE BIOTEK LTD. share is ₹5.26 and ₹1.83 as of 03 Jul, 2026.
What is the market cap of TRANSGENE BIOTEK LTD.?
The market capitalisation of TRANSGENE BIOTEK LTD. is ₹23.03 Crores as on 03 Jul, 2026.
What are the stock symbols of TRANSGENE BIOTEK LTD.?
The stock symbol of TRANSGENE BIOTEK LTD. is 526139 on the BSE, and the ISIN is INE773D01018.
What was yesterday's closing price for TRANSGENE BIOTEK LTD. shares ?
TRANSGENE BIOTEK LTD. shares closed yesterday at ₹3.04 on BSE
How to buy TRANSGENE BIOTEK LTD. shares?
To buy TRANSGENE BIOTEK LTD. shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy TRANSGENE BIOTEK LTD. shares on Holidays?
No, shares of TRANSGENE BIOTEK LTD. or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell TRANSGENE BIOTEK LTD. shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of TRANSGENE BIOTEK LTD.?
The PE and PB ratio of TRANSGENE BIOTEK LTD. is -13.82 and 2.75 respectively, as on 03 Jul, 2026, 15:29 IST.